The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Abstract Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4
(CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 …

Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of
immune-based therapies, including the widely used class of agents known as immune …

Purpose To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events in patients treated with …

Immunotherapy with monoclonal antibodies (MoAbs) targeting cytotoxic T lymphocyte-
associated antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its ligand …

During the past decade, immunotherapies have made a major impact on the treatment of
diverse types of cancer. Inflammatory toxicities are not only a major concern for Food and …

The enhancement of immune responses upon treatment with immune checkpoint inhibitors
can have the desired outcome of reinvigorating antitumour immune surveillance, but often at …

Highlights•Solid organ transplantation (SOT) patients or patients with active ADs have been
largely excluded from ICIs clinical trials because of the risk of allograft rejection or severe …